

MucilAir: a Novel Human 3D Airway Epithelium Model for Long Term Toxicity Testing

Samuel Constant, Ph.D., COO samuel.constant@epithelix.com

Epithelix Sàrl ■ 14, Chemin des Aulx – CH-1228 Plan les Ouates – Genève - Switzerland ■ +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 ■ epithelix@epithelix.com – www.epithelix.com

1

MucilAir





- ✓ Asthmatic
- ✓ Smokers
- ✓ COPD
- ✓ CF

Air-interface, differentiation



Similar, if not identical, ultra-structures as in the native tissues



In vitro, de novo Ciliogenesis on MucilAir 🥑



A time course of cilia formation monitored by anti-β-tubilin antibody







Various ions channels and cell markers are detected in our *in vitro* model of airway epithelium





- It closely mimics the morphology and functions of the normal human airway epithelium.
- It has a unique shelf-life of one year.
- It is easy to handle and maintain.
- Adapted to high-throughput screening and testing.
- Serum free.

Applications of MucilAir

Functional In Vitro Assays using MucilAir

- Toxicity Testing (cell viability and tissue integrity)
- Effect on ciliogenesis
- Effect on cilia beating (mucociliary clearance)
- Effect on Mucin secretion
- Measurement of pro-inflammatory mediators
- Simulation of chronic inflammation
- Electrophysiological activity (TEER, ion channels)
- Drug transport, etc.

MucilAir is a powerful tool to quantify Acute, Chronic and Long Term effect of molecules

- Cell viability (EC₅₀ & ET₅₀)
 ✓ Resazurin test (Quantitative)
- Tissue Integrity
 - ✓ Trans Epithelial Electrical Resistance (Quantitative)
- Cilia beating Monitoring
 - ✓ Visual Inspection (Qualitative)
- Time points
 - \checkmark Acute = 1 hour exposure
 - ✓ Chronic = Multiple 1 hour exposures
 - ✓ Long Term exposure (e.g. 24h, 48h, etc.)

Type of Compounds

- ✓ Solid, liquid
- ✓ Gas, nanoparticles, smoke: Cultex Chambers



Provider of human tissues reco



Acute Toxicity (1 hour Exposure)



Epithelix Provider of human tissues reconstituted in vitro

Chronic Toxicity (Multiple 1 hour Exposures)





Concentrations	0 mM	1 mM	2.5 mM	4 mM	5.5 mM	7 mM	8.5 mM	10 mM
Expo 1 (Day 0)	~	~	✓	~	~	~	EC ₂₅	-
Expo 2 (Day 7)	√	~	~	~	~	~		- M
Expo 3 (Day 14)	~	~	✓	~	 ✓ 			Ŵ
Expo 4 (Day 21)	~	~	✓	~	~			Ŵ
Expo 5 (Day 28)	~	~	✓	~				Ŵ
Expo 6 (Day 35)	✓	√	✓	√	A Contraction of the second se		See	

Inflammatory reaction on MucilAir 2 exposure modes Air Apical exposure Liquid

- Ideal for gas, particles.
- Typical reaction with liquids :





- Ideal for gas, particles.
- Typical reaction with liquids :

- Ideal for liquids
- No inflammation induced by vehicle





Our primary *in vitro* epithelium responds to pro-inflammatory mediators (TNF- α) in a physiological manner



A time course of IL-8 secretion (an inflammatory marker) after 30 minutes of TNF- α stimulation on a 3 months old epithelium. Note that this same epithelium can be reused to simulate chronic inflammation.



Enzyme-linked lectin assay (ELLA)

The test is based on the affinity of lectins for mucins. It allows the quantitative measurement of the secreted mucins.

- Acute, long term or chronic exposition
- Positive control : ATP stimulation



Molecule effect on Mucociliary clearance





- Phase contrast or using fluorescent particles
- Direct measurement of particles velocity

Electrophysiology on MucilAir



The cells from our *in vitro* epithelium show typical electrophysiological responses to ion channel inhibitors and activators



Current measurement in modified Ussing chamber



- Amiloride (sodium channel inhibitor) reduces the current.
- Isoproterenol, a CFTR activator (chloride channel) increases current.
- Bumetanide, a general channel blocker, abrogates the total channel current activities.

Evaluation of drug transport across MucilAir



Time course of the rate of permeation of Atenolol from the apical to basal lateral side during a period of 90 min (triplicate).

- LC/MS detection
- High reproducibility

Epithelix

Provider of human tissues reconstituted in vitro

Acknowledgements





- Ludovic Wiszniewski, Ph.D., CEO
- Song Huang, Ph.D., CSO

- Jean-Paul Derouette, Ph.D.
- Mireille Caul-Futy



